
Market Briefing

Powering Precision Medicine: Trends Shaping the CGT Market



Strategic Insights into the Global CGT Landscape




Confidential June 2025

Global Market Landscape: Cell and Gene Therapy

The global Cell and Gene Therapy (CGT) market is projected to grow at ~22% CAGR, reaching USD 53.7 Bn by 2026, driven by rising adoption, regulatory support, and strategic collaborations across therapeutic areas

Global Cell and Gene Therapy Market Size

2022-26 | Values in USD Bn



🗰 aranca

Source: Cell and Gene Therapy on the Ascent – CRISIL, Evaluate Pharma, American Society of Cell and Gene Therapy, CiteLine

Deals Landscape in the CGT Space

The CGT space witnessed robust deal activity from 2022 to 2024 with financing rounds peaking in Q1 2024 while alliance deals remained steady across guarters and acquisitions continued at a lower but stable pace



85 72 68 67 64 59 56 54 54 51 49 41 40 40 40 35 34 34 34 12 10 9 9 9 8 8 8 7 7 6 Q2 2024 Q12022 Q12023 Q2 2023 Q3 2023 Q1 2024 Q2 2022 Q3 2022 Q4 2022 Q4 2023 Q3 2024 Q4 2024 -Financing* ----Acquisitions Alliances

aranca

*Financings include public financings (IPOs and follow-ons) plus privately raised funding through venture rounds, debt offerings, or private investment in public equity

Source: American Society of Cell and Gene Therapy (Q1 2023, Q4 2023, Q4 2024 reports

2 Market Briefing: Powering Precision Medicine: Trends Shaping the CGT Market | June 2025

Acquisitions in the CGT Space

Between 2024 & 2025, AstraZeneca, Roche, & Novartis made major CGT acquisitions to expand portfolios in CAR-T & gene therapies, with deal values reaching up to \$1.1 billion – targeting oncology & neuromuscular diseases

Significant Acquisitions in the CGT Space 2022-24



EsoBiotec

Year: March 2025

- AstraZeneca agreed to acquire Belgium-based Esobiotec, a biotech company developing in vivo CAR-T cell therapies
- The acquisition includes an initial payment of \$425 million, with up to \$575 million in milestone-based payments





Year: November 2024

Year: November 2024

- Roche announced acquisition of Poseida Therapeutics, a U.S.-based company specializing in allogeneic CAR-T cell therapies
- · This acquisition aims to bolster Roche's portfolio in immune cell therapies, particularly for blood cancers

U NOVARTIS




- Novartis announced the acquisition of Kate Therapeutics in a deal worth up to \$1.1 billion
- The acquisition is aimed at strengthening Novartis's gene therapy pipeline, particularly in the area of inherited neuromuscular diseases

ille arar

Source: American Society of Cell and Gene Therapy (Q1 2023, Q4 2023, Q4 2024 reports

Global Cell and Gene Therapy Approvals

As of 2024, 111 CGTs have been approved globally, primarily for oncology & rare diseases, with North America accounting for over 65% of approvals, followed by Europe and Asia-Pacific




Source: Cell and Gene Therapy on the Ascent – CRISIL, Evaluate Pharma, American Society of Cell and Gene Therapy, CiteLine

aranca

Global Cell and Gene Therapy Pipeline Landscape

Over 3,900 CGT candidates are in development with ~70% in early stages and ~60% focused on cancer while North America and Asia-Pacific together account for ~65% of global pipeline activity



🗰 aranca

CGT Therapies

Source: Cell and Gene Therapy on the Ascent – CRISIL, American Society of Cell and Gene Therapy, CiteLine, News Release,


Technologies in Pipeline Programs of Cell and Gene Therapy

2024

Lentivirus & AAV are the leading gene therapy delivery technologies while CAR-T dominates GM cell therapies; hematopoietic & mesenchymal stem cells are the most used types in non-GM cell therapy programs

Technologies in Cell Therapy Programs

Delivery Technologies in GT**



🗰 aranca

Source: American Society of Cell and Gene Therapy, CiteLine, News Releases

Examples of Technological Innovations

Companies are innovating across non-viral delivery, gene, & cell therapies through electroporation, mRNA platforms, gene-agnostic approaches, & engineered therapies to enhance safety, efficacy, & accessibility across disease areas

Examples of Tech Innovations by CGT Companies

Non-Viral Delivery Methods

MaxCyte's Flow Electroporation® Technology

- Platform enables efficient delivery of molecules like nucleic acids and geneediting tools into cells
- Supports both ex- and in-vivo applications
- Agnostic to cell type & gene manipulation technology, making it versatile for various therapeutic approaches

mRNA and LNP Delivery Technology

- Abnova's nanoCAR-T mRNA service uses mRNA vectors instead of traditional lentiviral vectors
- Enhanced CAR-T cell expression, persistence, & therapeutic efficacy – making it scalable and cost-effective

Gene Therapy Innovations

Modifier Gene Therapy Platform

- Ocugen's platform uses nuclear hormone receptors (NHRs)
- Aim to address retinal diseases like dry AMD and Stargardt disease, offering a gene-agnostic approach

Cell Therapy Innovations

Allogeneic CAR-T Therapies

- CARsgen's THANK-uCAR® platform developing allogeneic CAR T-cell products,
- Aim to address challenges like NKG2A expression levels, improving therapeutic efficacy for multiple myeloma

Next-Generation TIL Cell Therapy

- Iovance Biotherapeutics advancing TIL (tumor-infiltrating lymphocyte) cell therapies with genetic modifications, such as PD-1 inactivation
- · Aim to enhance efficacy in solid tumors

Source: American Society of Cell and Gene Therapy, CiteLine, News Releases

aranca

Emergence of Digital Intervention and Artificial Intelligence

AI & digital tools are transforming CGT manufacturing by improving efficiency, scalability, & quality through innovations like AI-engineered proteins, robotics, & ML with companies like Bio-Techne & OmniaBio leading the integration

Artificial Intelligence (AI) and Digital Integration in CGT Manufacturing

- Al and digital tools are being increasingly integrated into cell and gene therapy (CGT) to enhance R&D efficiency, manufacturing scalability, and product consistency.
- Technologies such as AI-driven protein and AAV capsid design, machine learning (ML) for process optimization, closed-system automation, and real-time biosensor analytics are streamlining development workflows.
- Companies like Bio-Techne, and OmniaBio are using these tools to improve safety, reduce costs, and accelerate time-to-market. These innovations are helping overcome traditional CGT bottlenecks in quality control, scalability, and regulatory compliance.

biotechne

- Expanded R&D Systems portfolio to include Al-engineered designer proteins, (e.g., IL-2 Heat Stable Agonist, Activin A Hyperactive, etc.)
- These designed using generative AI trained on extensive proteomic data – enhanced stability, receptor affinity, & performance in cell culture applications
- Its ProPak[™] GMP cytokines provided in **dose-optimized**, **single-use bags with weldable tubing**
- Facilitate closed-system manufacturing for cell therapies minimizes contamination risks and supports scalable, efficient production processes

OmniaBio


- Employs **advanced robotics** to automate various manufacturing tasks, utilizes **biosensors** to monitor and ensure the standardization and quality control of biomanufacturing processes
- Leverages **machine learning algorithms** to analyze extensive datasets from the production cycle
- Partnership with Somite Therapeutics provides expertise in induced pluripotent stem cell (iPSC) technology and AI to support development of cell replacement therapy for Duchenne Muscular Dystrophy (DMD)

Source: American Society of Cell and Gene Therapy, CiteLine, News Releases

maranca

Thought Leadership

Aranca's Insights and Thought Pieces on the CGT Market



ARTICLE

Cell and Gene Therapy – The Next Frontier in Lifesciences

This article explores CGT's clinical pipeline, strategic collaborations, and global investment landscape.



ARTICLE


Gene Therapy: Revolutionizing Type 1 Diabetes <u>Care</u>

This article explores gene therapy's role in treating Type 1 diabetes through cell reprogramming and DNA editing, driven by investments and innovation..




TEAR SHEET Future Developments in Gene Therapy

This tear sheet explores gene therapy's potential, challenges, & recent advances in novel treatments.



TEAR SHEET Developments in Cell Based Therapies

This tear sheet explores CGT's market growth, clinical pipeline, partnerships, & investment trends.



TEAR SHEET

<u>CGT Manufacturing Landscape in Singapore:</u> <u>Current Challenges & Future Landscape</u>

This tear sheet provides insights into challenges with CGT scale-up in Singapore, & efforts by the country to standardize manufacturing & build local ecosystem.



THEMATIC REPORT

<u>Gene Therapy – Advanced Treatments for a New</u> <u>Area</u>

This report covers gene therapy challenges, delivery methods, outlook, key investors, & approved drugs.



500+ Strong team of professionals across multi-disciplinary domains 2500+ Global clients **120+** Sectors and sub-sectors researched by our analysts 80+ Countries where we have delivered projects

aranca

ABOUT ARANCA



Growth Advisory CXOs in Strategy, SBUs, Sales, Marketing, CI/MI, Innovation



Technology | IP Research & Advisory

R&D, Tech Scouting, Open Innovation, IP Teams, Product Development



Valuation & Financial Advisory

CFOs in Start-ups, PE/VC Firms, Corporate M&A Teams, Mid-market Companies



Investment Research & Analytics

Brokerage, Hedge Funds, IRPs, I-Banks, AMCs, Investor Relations



Vibin Theril Associate Vice President – Growth Advisory

> +91 9819350761 vibin.theril@aranca.com



Kartikeya Rao

Engagement Lead – Growth Advisory

+91 9022654622 kartikeya.rao@aranca.com



Vasuda Venkitakrishnan

Engagement Lead – Growth Advisory

+91 9820967433 vasuda.v@aranca.com



Decide Fearlessly

From startups to the Fortune 500, private equity and global financial firms, Aranca is the trusted research and advisory partner for over 2500 companies

www.aranca.com

Haranca

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.